Table 5

Principal outcomes: for total trial population, and stratified by country, completed weeks gestation at delivery, inborn/outborn, age at entry, and with or without cerebral scan abnormality at trial entry

Etamsylate (n=165) Control (n=169)
Known death or impairment or disability58/165 (35)57/169 (34)
 France33/90 (37)30/91 (33)
 Greece25/75 (33)27/78 (35)
 <29 completed weeks gestation at delivery18/31 (58)18/35 (51)
 =29 completed weeks gestation at delivery40/134 (29)39/134 (29)
 Inborn18/62 (29)25/73 (34)
 Outborn40/103 (39)32/96 (33)
 Age at entry
  <1 hour6/21 (29)10/23 (43)
  ⩾1 hour51/143 (36)47/145 (32)
  Not known1/1 (100)0/1 (0)
 With cerebral scan abnormality at trial entry23/57 (40)30/61 (49)
 Without cerebral scan abnormality at trial entry35/108 (32)27/108 (25)
Known death or severe impairment or disability47/165 (28)41/169 (24)
 France25/90 (28)19/91 (21)
 Greece22/75 (29)22/78 (28)
 <29 completed weeks gestation at delivery15/31 (48)17/35 (49)
 =29 completed weeks gestation at delivery32/134 (24)24/134 (18)
 Inborn15/62 (24)20/73 (27)
 Outborn32/103 (31)21/96 (22)
 Age at entry
  <1 hour5/21 (24)7/23 (30)
  ⩾1 hour41/143 (29)34/145 (23)
  Not known1/1 (100)0/1 (0)
 With cerebral scan abnormality at trial entry20/57 (35)22/61 (36)
 Without cerebral scan abnormality at trial entry27/108 (25)19/108 (18)
  • Values in parentheses are percentages.